The evidence base on COVID-19 seeks to provide clinicians, program managers, and community members with credible up-to-date information on the relationship between viral hepatitis and liver disease with COVID-19. 

Synthesis on COVID-19 and liver disease

Researchers and experts from across the world have been working rapidly to understand theinteraction of co-morbidities and COVID-19, including liver disease. In this synthesis published in April, Dr. Ward summarized the current status of the evidence on COVID-19 and liver disease.

Clinical Liver Disease series

The Coalition worked with Clinical Liver Disease, a journal of AASLD, to publish an 8 article series related to COVID-19 and liver disease.

Dr. Ward, Director of the Coalition, co-authored two of these articles:

Read the full series here.

Other resources

AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID-19 Infection in Patients with Liver Disease

Analysing and using routine data to monitor the effects of COVID-19 on essential health services: Practical guidance

Last day updated 04 Feb 2021
CLD Author Interview

Impact of COVID-19 Response on Hepatitis Prevention Care and Treatment: Results From Global Survey of Providers and Program Managers

In this month's "Innovations in Hepatitis Elimination" author interview on February 11th, Dr. Ward reviewed key findings from the Coalition's global survey of hepatitis providers and program managers on the impact of COVID-19. We also heard from some of the survey respondents who will describe their experience in delivering hepatitis services during the pandemic, including the challenges they faced and the mitigation strategies they found effective in maintaining access to care for their patients.